Biopharmaceutical company RedHill Biopharma Ltd (Nasdaq:RDHL) reported on Wednesday the inclusion of the Talicia (omeprazole magnesium, amoxicillin and rifabutin) to its Contract Drug List (CDL) for H. pylori treatment, with no prior authorization required.
Effective 1 October 2021, the coverage for Talicia was initiated by the company's Medi-Cal - California's Medicaid Health Care programme covering 2m patients. H. pylori is a bacterial infection that affects 35% of the U.S. population, with about 2m patients treated annually.
The company said Talicia is eligible for a total of eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is covered by U.S. patents which extend patent protection until 2034.
According to the company, Talicia is the only rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria to clarithromycin-based therapies. Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole).
Under the company's pivotal Phase 3 study, Talicia demonstrated 84% eradication of H. pylori infection in the intent-to-treat group vs 58% in active comparator arm. Minimal to zero resistance to rifabutin, a key component of Talicia, was also detected. The subjects who were confirmed adherent to their therapy had response rates of 90.3% in the Talicia arm vs. 64.7% in the active comparator arm.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer